As research continues to clarify mechanisms, refine formulations and define long-term risks and benefits, GLP-1based therapies may ultimately serve as a model for a new generation of treatmentsones that work not by targeting a single pathway, but by engaging the bodys interconnected systems as a whole
In practice, the net effect in the clinical data was improved glycemic control, but individual responses vary
In preclinical in vitro work, GIPR signalling has been associated with lipid partitioning in adipocyte models and potentiation of insulin secretion under hyperglycaemic conditions
Diabetes Care 2021;44:290-6.ArticlePubMed 94
Its true that GLP-1s began as a type 2 diabetes treatment, among other conditions besides weight loss
It's not a medical practice